EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing

Coralie Fontaine, Anna Gosset, Morgane Davezac, Mélissa Buscato, Virginie Grouthier, Marie-Ange Renault iD, Daniel Henrion, Florence Trémollières, Michael Schumacher iD, Françoise Lenfant, Jean-François Arnal

Cardiovascular Research · 2025

DOI: 10.1093/cvr/cvaf086 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Coralie Fontaine und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institut National de la Santé et de la Recherche Médicale (Inserm) U1297, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), University …. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Aging, Gonadal Steroid Hormones, Estrogen Replacement Therapy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 212 Literaturangaben. Gefördert von: University of Toulouse, Fondation pour la Recherche Médicale, Fondation de France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ageing plays a critical role in the deterioration of artery function and structure, and clearly represents the first cardiovascular (CV) risk factor in men but also in women. Coronary and cerebral arteries are particularly prone to atheroma, and the tissues they perfuse are particularly vulnerable to ischaemia. In both sexes, the age-related decrease in sex hormones (menopause and andropause) has deleterious effects on CV health. The extent to which hormonal supplementation can limit the CV risks increased by ageing remains controversial. The Women Health Initiative study, the main clinical intervention designed to evaluate the benefit/risk ratio of hormone treatment after menopause, revealed in 2002 an unexpected increase in CV events in aged women (>70 years) given estrogens plus a peculiar synthetic progestin medroxyprogesterone acetate, whereas estrogens alone were not harmful but even protective in younger women (<60 years). This pointed out the double problem of the progestin (now natural progesterone is preferred) and of the age. The clinical situation is not yet clear for testosterone and CV disease in men. Related to these questions, we will analyse and summarize: (i) the importance of the doses and concentrations of estrogens and testosterone, both in humans and in experimental models, allowing to define relevant/physiological or pharmacological actions of sex hormones in respect to their medical modulations in practice; (ii) the main clinical studies conducted with estrogens or androgens, in terms of CV protection and the impact of age on these effects; (iii) the mechanisms underlying these actions; (iv) the gender-affirming hormone therapy, as these sex hormones are the cornerstone of gender transition care management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesAgingGonadal Steroid HormonesEstrogen Replacement TherapyHormone Replacement TherapyCardiovascular SystemHumansFemaleMaleHeart Disease Risk FactorsAge FactorsRisk AssessmentAnimalsEstrogensSex FactorsTestosteroneAgedProtective FactorsMiddle Aged

Stichwörter der Autor:innen

AgeingAndrogensCardiovascular diseaseEstrogensMenopauseSex hormone

Substanzen

Gonadal Steroid HormonesEstrogensTestosterone

Autor:innen und Institutionen

  • Institut National de la Santé et de la Recherche Médicale (Inserm) U1297, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), University of Toulouse, Toulouse CHU, 1 avenue Jean Poulhès, 31 400 Toulouse, Fra…
  • University of Bordeaux, Inserm, Biology of CV Diseases, UMR 1034 Pessac F-33600, France.
  • University of Angers, MITOVASC department, CarMe Team, Inserm U1083, UMR CNRS 6015, Angers, France.
  • Inserm U1195, University Paris-Saclay, Le Kremlin-Bicêtre, France.

ORCID-Profile: Marie-Ange Renault, Michael Schumacher

Förderung

  • University of Toulouse
  • Fondation pour la Recherche Médicale
  • Fondation de France
  • French National Research Agency
  • Région-Occitanie-Midi Pyrénées
  • European Union

Zitieren

APA

Fontaine, C., Gosset, A., Davezac, M., Buscato, M., Grouthier, V., Renault, M. A., Henrion, D., Trémollières, F., Schumacher, M., Lenfant, F., & Arnal, J. F. (2025). From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf086

Vancouver

Fontaine C, Gosset A, Davezac M, Buscato M, Grouthier V, Renault MA, et al. From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf086

BibTeX
@article{Fontaine2025,
  author = {Fontaine, Coralie and Gosset, Anna and Davezac, Morgane and Buscato, Mélissa and Grouthier, Virginie and Renault, Marie-Ange and Henrion, Daniel and Trémollières, Florence and Schumacher, Michael and Lenfant, Françoise and Arnal, Jean-François},
  title = {From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvaf086}
}
Kostenlos starten →